Condition: Progressive Pulmonary Fibrosis · Interstitial Lung Disease · Sponsor: United Therapeutics
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
This description comes directly from the study's public registry record.
United Therapeutics Global Medical Information · 919-485-8350 · clinicaltrials@unither.com
Always discuss trial participation with your own doctor first.
| UAB Lung Health Center | Birmingham, Alabama, United States | Recruiting |
| Banner University Medical Center Phoenix Lung Institute | Phoenix, Arizona, United States | Recruiting |
| Norton Thoracic Institute | Phoenix, Arizona, United States | Recruiting |
| Peter Morton Medical Building | Los Angeles, California, United States | Recruiting |
| NewportNativeMD, Inc. | Newport Beach, California, United States | Recruiting |
| University of California Irvine Medical Center | Orange, California, United States | Recruiting |
| Paradigm Clinical Research | Redding, California, United States | Recruiting |
| UC Davis Health Medical Center | Sacramento, California, United States | Recruiting |
| Paradigm Clinical Research | San Diego, California, United States | Recruiting |
| Stanford University Medical Center | Stanford, California, United States | Recruiting |
| Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Ascension Medical Group St. Vincent's Lung Institute | Jacksonville, Florida, United States | Recruiting |
+ 153 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05943535